Deals · Updated 23 Oct, 06:49 pm IST
Pathos AI partners with Bristol Myers, Tempus AI and raises $237M for drug-development tools
Why it matters for readers: If you're curious about AI in medicine, this is a concrete example of companies using patient data and models to study disease and improve trials.
- Pathos AI raised $237 million in a Series E round led by Bristol Myers that values the company at about $3 billion.1
- Pathos will collaborate with Bristol Myers Squibb and Tempus AI to develop AI tools for Alzheimer's disease and other neurological disorders.1
- Tempus will build a dataset from hundreds of thousands of patients with neurological disorders, which Pathos will license under a five-year, $55 million agreement.1
- Pathos will apply its AI platform, Pathos Foundry, to study the Tempus dataset at scale, generate and test hypotheses, and inform design of more targeted, adaptive clinical trials.1
- Bristol Myers gains non-exclusive strategic access to Pathos Foundry across its portfolio and three-year exclusive rights for its neuroscience programs.1
Get a brief like this every morning
Uzha reads hundreds of sources and gives you the stories that matter for your work, with every source linked. Free.
Get started